AI: DeepSeek (deepseek-chat)

Q: {
  "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n## Analysis Against Guidelines\n\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\n### Very Important Recommendations  \n1. **Different management plan** - Discontinue routine ursodeoxycholic acid (UDCA) for perinatal outcomes, as it does not significantly impact them per the guideline.  \n   Reason: The guideline states, \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\" UDCA may still be used for symptomatic relief but should not be presented as improving fetal outcomes.  \n\n2. **Improved patient advice** - Clarify that fetal ultrasound and CTG do not predict or prevent stillbirth in ICP, emphasizing fetal movement monitoring instead.  \n   Reason: The guideline explicitly states, \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\" The current plan includes unnecessary routine CTGs and growth scans.  \n\n3. **Different management plan** - Adjust delivery timing recommendations based on peak bile acid levels (consider earlier delivery only if ≥100 µmol/L).  \n   Reason: The guideline recommends, \"The risk of stillbirth in ICP increases when serum bile acid concentrations are 100 micromol/L or more.\" The current plan suggests delivery at 36–37 weeks if bile acids <100 µmol/L, but the guideline does not mandate this unless other risk factors are present.  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Document baseline bile acid levels from booking bloods (if available) to establish a reference.  \n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels. While this is her first ICP episode, baseline data would still be useful.  \n\n2. **Improved patient advice** - Counsel on the increased risk of pre-eclampsia and gestational diabetes, recommending regular monitoring.  \n   Reason: The guideline notes, \"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\" This was not mentioned in counseling.  \n\n3. **Different management plan** - Avoid routine additional investigations (e.g., clotting screen, full blood count) unless clinically indicated (e.g., severe symptoms or comorbidities).  \n   Reason: The guideline states, \"Additional investigations not recommended unless itch is severe or associated with comorbidities.\"  \n\n### Less Important Recommendations  \n1. **Improved patient advice** - Provide links to ICP Support and RCOG resources for patient education.  \n   Reason: The guideline lists \"Information for women and families from ICP Support and RCOG\" as a useful resource.  \n\n2. **Additional information needed** - Consider hepatitis C testing only if risk factors are present (not routinely recommended).  \n   Reason: The guideline notes, \"Routine use of other investigations, including for hepatitis C, is no longer recommended.\"  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Mention the small increased lifetime risk of hepatobiliary/immune-mediated diseases, though this is less urgent for current management.  \n   Reason: The guideline notes this association, but it does not impact immediate obstetric care.  \n\n### Summary of Critical Changes Needed:  \n- **Stop presenting UDCA as a fetal outcome modifier** (very important).  \n- **De-emphasize CTG/growth scans** and focus on fetal movement monitoring (very important).  \n- **Adjust delivery timing logic** to align with bile acid thresholds (very important).  \n- **Add pre-eclampsia/gestational diabetes counseling** (somewhat important).  \n\nThese changes align the note with the guideline’s evidence-based, risk-stratified approach.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 48 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
  "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- Ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
  "transcript_length": 3421,
  "analysis_length": 3912,
  "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
  "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
}

A: {
  "suggestions": [
    {
      "id": "1",
      "originalText": "Start ursodeoxycholic acid 500 mg BID while awaiting results.",
      "suggestedText": "Consider ursodeoxycholic acid 500 mg BID for symptomatic relief while awaiting results (not for fetal outcomes).",
      "context": "Guideline states UDCA should not be presented as improving fetal outcomes, though may be used for symptomatic relief",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP"
    },
    {
      "id": "2",
      "originalText": "Increase surveillance: twice-weekly CTGs and weekly growth scans.",
      "suggestedText": "Focus monitoring on fetal movements rather than routine CTGs/growth scans as these don't predict stillbirth in ICP.",
      "context": "Guideline states fetal ultrasound and CTG do not predict or prevent stillbirth in ICP",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP"
    },
    {
      "id": "3",
      "originalText": "Aim for delivery at 36–37 weeks if bile acids <100 µmol/L.",
      "suggestedText": "Consider delivery timing based on peak bile acid levels (earlier delivery only if ≥100 µmol/L unless other risk factors present).",
      "context": "Guideline recommends adjusting delivery timing based on bile acid thresholds",
      "category": "modification",
      "priority": "high",
      "guidelineReference": "The risk of stillbirth in ICP increases when serum bile acid concentrations are 100 micromol/L or more"
    },
    {
      "id": "4",
      "originalText": "Counseling Provided: Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.",
      "suggestedText": "Counseling Provided: Discussed nature of obstetric cholestasis, increased risk of stillbirth in twin pregnancies, and need to monitor for pre-eclampsia/gestational diabetes.",
      "context": "Guideline notes increased risk of pre-eclampsia and gestational diabetes in ICP",
      "category": "addition",
      "priority": "medium",
      "guidelineReference": "Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes"
    },
    {
      "id": "5",
      "originalText": "Full blood count and clotting screen (due to potential risk of coagulopathy).",
      "suggestedText": "Consider additional investigations only if itch is severe or comorbidities present.",
      "context": "Guideline recommends against routine additional investigations unless clinically indicated",
      "category": "modification",
      "priority": "medium",
      "guidelineReference": "Additional investigations not recommended unless itch is severe or associated with comorbidities"
    },
    {
      "id": "6",
      "originalText": "Provided written information and contact details for triage if symptoms worsen.",
      "suggestedText": "Provided written information (including ICP Support and RCOG resources) and contact details for triage if symptoms worsen.",
      "context": "Guideline lists specific patient education resources",
      "category": "addition",
      "priority": "low",
      "guidelineReference": "Information for women and families from ICP Support and RCOG"
    }
  ]
}

--- Token Usage Report ---
Prompt tokens: 1850
Completion tokens: 756
Total tokens: 2606
Estimated cost: $0.001303